Investors
Investor Relations
RudaCure is an AI drug discovery company targeting membrane proteins — ion channels and GPCRs. We are preparing for IPO with one targeting principle applied across dry eye, chronic pain, psoriasis and rare neurological disease, on a scalable AI platform.
Strategic Roadmap
2026 Milestones
IPO Underwriter Selection & Full-Scale IPO Launch
RCI001 Korea Phase 2 Clinical Trial Entry
RCI002 ODD Designation
RCI002 Global Licensing
Why Invest
The Investment Case
Proven Licensing Track Record
Hanlim Pharma RCI001/RCI001U domestic licensing. multinational veterinary pharmaceutical licensing completed. Expanding global partnerships.
Diversified Revenue Streams
Human pharmaceuticals, veterinary medicines, API supply, and CRO services for revenue diversification and sustainable growth.
Scalable AI Platform
RuCIA enables rapid candidate identification with significantly reduced cost and development time.
Differentiated Local Analgesia Strategy
Intra-articular delivery lowers systemic exposure in a regulatory environment where FDA/EMA prioritize reducing reliance on systemic opioids.
Company Snapshot
Key Facts
| Founded | 2018 |
| Cumulative Gov't Grants | ~$4M+ |
| Key Licensing | Hanlim Pharma (RCI001/RCI001U), Multinational Vet Pharma (RCI001AH) |
| IPO Preparation | Underwriter Selected (2025) |
| Core Assets | RuCIA Platform + 3 Pipelines |
| Patent Portfolio | Korea / Japan / US |
Strategic Partners
Partners
“We don’t just treat symptoms; we heal the source of sensory signals.”
For investor inquiries, partnership proposals, or IR materials, please contact us.